Business Context and Reporting Period
This Form 8-K filing by Genprex, Inc. (GNPX) is dated November 25, 2025. The report addresses the company's status regarding continued listing on the Nasdaq Capital Market following previous notifications of non-compliance with specific listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status rather than financial performance metrics.
Material Changes and Listing Status
- Bid Price Compliance: The Nasdaq Hearings Panel determined that the Company has regained compliance with the $1.00 Minimum Bid Price requirement (Listing Rule 5550(a)(2)).
- Stockholders' Equity Exception: The Panel approved an exception until December 31, 2025, for the Company to demonstrate long-term compliance with the minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).
- Future Extension Possibility: The Company may request a further extension of continued listing through February 9, 2026, subject to the Panel's discretion.
Outlook, Risks, and Management Commentary
- Capital Raising Needs: Management believes the Company will need to engage in additional capital raising transactions to regain compliance with the Stockholders' Equity Requirement.
- Financing Uncertainty: There is no guarantee that such financing will be available on acceptable terms or at all.
- Delisting Risk: The Panel reserves the right to reconsider the terms of the exception if events occur that make continued listing inadvisable. There is no assurance that an extension beyond December 31, 2025, will be granted.
- Reporting Obligations: The Company intends to provide prompt notification of any significant events that may call into question its ability to satisfy the terms of the exception.
Investor Verification Checklist
- Verify the current stock price to ensure it remains above the $1.00 minimum bid price threshold.
- Monitor upcoming filings for announcements of capital raising activities or financing agreements.
- Check for any further communications from the Nasdaq Hearings Panel regarding the December 31, 2025, deadline.
- Review the most recent Form 10-K and 10-Q for detailed financial statements and risk factors not included in this 8-K.